Video Center

The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Sattva Neelapu, MD, on new targets being evaluated which could make CAR-T therapies more effective

Dr. Neelapu, Associate Professor and Director of Laboratory and Translational Research, Department of Lymphoma/Myeloma, MD Anderson Cancer Center, provides insight on which targets besides CD-19 are under evaluation and could make CAR-T therapies more effective

Published: 15 December 2016

Recent Videos: ASH Conference Coverage

video

Sattva Neelapu, MD, on new targets being evaluated which could make CAR-T therapies more effective

Dr. Neelapu, Associate Professor and Director of Laboratory and Translational Research, Department of Lymphoma/Myeloma, MD Anderson Cancer Center, provides insight ...

video

Sattva Neelapu, MD, on the possibility to enhance T-cell proliferation for a higher response rate

Dr. Neelapu, Associate Professor and Director of Laboratory and Translational Research, Department of Lymphoma/Myeloma, MD Anderson Cancer Center, weighs in ...

video

Sattva Neelapu, MD, on when we may see widespread availability of CAR-T therapies

Dr. Neelapu, Associate Professor and Director of Laboratory and Translational Research, Department of Lymphoma/Myeloma, MD Anderson Cancer Center, talks about ...

video

Nikhil C. Munshi, MD, discusses his optimism about the use of immunotherapies to treat MM patients

Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, discusses optimism about the use of immunotherapies ...

video

Nikhil C. Munshi, MD, on whether we can start to associate the word “cure” with MM patients

Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, provides opinion on if the word “cure” ...

video

Nikhil C. Munshi, MD, discusses the exciting news at ASH multiple myeloma patients

Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, on exciting news coming out of ASH ...

video

Nikhil C. Munshi, MD, on how physicians should sequence therapies in untreated MM patients

Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, provides viewpoint on how physicians should sequence ...

video

Lauren Pinter-Brown, MD, explains refractory vs. relapsed peripheral T-cell lymphoma patients

Dr. Pinter-Brown, Health Sciences Professor of Medicine and Dermatology; Chao Family Comprehensive Cancer Center, University of California, Irvine, explains the ...

video

Lauren Pinter-Brown, MD, on improving quality of life for patients with T-cell lymphomas

Dr. Pinter-Brown, Health Sciences Professor of Medicine and Dermatology; Chao Family Comprehensive Cancer Center, University of California, Irvine, explains how ...

video

Swaminathan Iyer, MD, discusses exciting new CLL treatment options

Dr. Iyer, Co-Director Cockrell Center for Advanced Therapeutics, talks about exciting new treatment options for CLL

video

Swaminathan Iyer, MD, relays the latest T cell lymphomas news coming out of ASH 2016

Dr. Iyer, Co-Director Cockrell Center for Advanced Therapeutics, discusses the latest updates in T cell lymphomas that is being presented ...

video

Swaminathan Iyer, MD, discusses intriguing data on CLL presented at ASH 2016

Dr. Iyer, Co-Director Cockrell Center for Advanced Therapeutics, on intriguing data for CLL coming out of ASH 2016

video

Alexander Perl, MD, on AML trial results presented at this year’s ASH meeting

Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, on which ASH AML trial results have been ...

video

Alexander Perl, MD, discusses treatment options for patients with FLT3-ITD positive AML

Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, gives his feedback on trials looking at treatment ...

video

Alexander Perl, MD, on prognosis, diagnosis and treatment strategies for AML

Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, discusses patient and hematologist challenges in the prognosis, ...

video

Chadi Nabhan, MD, on payers using clinical pathways in hematological malignancies vs solid tumors

Dr. Nabhan, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, on if payers are using clinical pathways in ...

video

Chadi Nabhan, MD, on attention grabbing presentation in CLL at ASH 2016

Dr. Nabhan, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, on which ASH 2016 CLL presentations have caught ...

video

Alexander Perl, MD, discusses treatment options for AML patients

Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, weighs in on AML treatment options in patients ...

video

Jeffrey Jones, MD, on the exciting CLL clinical advances presented at ASH 2016

Dr. Jones, Associate Professor of Medicine, The Ohio State University, The James Cancer Hospital, on which clinical advances in CLL ...

video

David Miklos, MD, on developing an orphan drug for a small population of patients

Dr. Miklos, Associate Professor of Medicine, Blood and Marrow Transplantation, Stanford University, relays his pharmaceutical company experience in developing an ...

video

Miles Prince, MD, on if any positive news for CTCL patients will be coming out of ASH 2016

Dr. Prince, Professor, The University of Melbourne and Monash University, on ASH 2016 positive news for CTCL patients

video

Miles Prince, MD, on how CTCL patients will be impacted by treatment with brentuximab vedotin

Dr. Prince, Professor, The University of Melbourne and Monash University, on how he expects CTCL patients to be impacted by ...

video

Jane Winter, MD, on how immunotherapies are being incorporated into treatment for lymphoma patients

Dr. Winter, MD, Northwestern Univ. Feinberg School of Medicine, Professor of Medicine, on the incorporation of immunotherapies into treatment algorithms ...

video

C. Ola Landgren, MD, PhD, on his optimism about the use of immunotherapies to treat MM patients

Dr. Landgren, Chief, Myeloma Service, Memorial Sloan Kettering, discusses his optimism around the use of of immunotherapies treatment for multiple ...

video

C. Ola Landgren, MD, PhD, on how physicians should manage patients who test MRD negative

Dr. Landgren, Chief, Myeloma Service, Memorial Sloan Kettering, discusses the best way for physicians to manage MRD negative patients

video

C. Ola Landgren, MD, PhD, on which multiple myeloma should be tested for MRD and why

Dr. Landgren, Chief, Myeloma Service, Memorial Sloan Kettering, talks about which and why, multiple myeloma patients should be tested for ...

video

C. Ola Landgren, MD, PhD, provides insight into the treatment algorithm for smoldering MM patients

Dr. Landgren, Chief, Myeloma Service, Memorial Sloan Kettering, on the current treatment algorithm for smoldering myeloma patients

video

Andrzej Jakubowiak, MD, PhD, discusses which new drugs are most compelling

Dr. Jakubowiak, University of Chicago, Professor of Medicine; Director, Myeloma Program, talks about the new drugs worth mentioning

video

Andrzej Jakubowiak, MD, PhD, relays big changes in the evolving role of immunomodulatory therapy

Dr. Jakubowiak, University of Chicago, Professor of Medicine; Director, Myeloma Program, on big changes discovered in the ASH meetings in ...

video

Eunice Wang, MD, on the importance of drug potency in the treatment of FLT3-ITD positive AML

Dr. Wang, Professor of Oncology, Department of Medicine Chief, Leukemia Service, Roswell Park Cancer Center, talks about how important drug ...

video

Matthew Davids, MD, MMSc, talks about his ASH 2016 presentations

Dr. Davids, Associate Director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, discusses ...

video

Parameswaran Hari, MD, on stem cell transplant and the treatment of high and low risk MM patients

Dr. Hari, Professor of Hematology, Medical College of Wisconsin, talks about how stem cell transplant figures into the treatment algorithm ...

video

Parameswaran Hari, MD, discusses stem cell transplantation and the treatment of myeloma

Dr. Hari, Professor of Hematology, Medical College of Wisconsin, explains how to integrate stem cell transplantation into the treatment of ...

video

Aref Al-Kali, MD, explains sustained inhibition of FLT3 when treating AML patients

Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, reflects on the BEAT AML master trial and individualized therapy for AML ...

video

Aref Al-Kali, MD, reflects on the BEAT AML master trial and individualized therapy for AML patients

Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, reflects on the BEAT AML master trial and individualized therapy for AML ...

video

Frederick Locke, MD, on the timing of when we could see widespread availability of CAR-T therapies

Dr. Locke, Director of Research and Service Chief of the Immune and Cellular Therapy (ICE-T) Program, Moffitt Cancer Center, provides ...

video

Frederick Locke, MD, on if CAR-T may replace transplantation when treating B-cell lymphomas

Dr. Locke, Director of Research and Service Chief of the Immune and Cellular Therapy (ICE-T) Program, Moffitt Cancer Center, talks ...

video

Frederick Locke, MD, explains the ZUMA-1 results and what it means to DLBCL patients

Dr. Locke, Director of Research and Service Chief of the Immune and Cellular Therapy (ICE-T) Program, Moffitt Cancer Center, speaks ...

video

Parameswaran Hari, MD, talks about which stem cell transplantation studies are most exciting in MM

Dr. Hari, Professor of Hematology, Medical College of Wisconsin, speaks to which stem cell transplantation studies are most exciting and ...

video

Michael Kauffman, MD, on Selinexor regulatory and commercialization plans

Dr. Kauffman, CEO Karyopharm Therapeutics, discusses the regulatory and commercialization plans for Selinexor

video

Edward Copelan, MD, on the most exciting presentations coming out of ASH 2016

Dr. Copelan, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, discusses which ASH 2016 presentations were the ...

video

Matthew Davids, MD, MMSc, on the potential benefits of utilizing checkpoint blockade

Dr. Davids, Associate Director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, relays ...

video

Shaji Kumar, MD, shares his thoughts on whether multiple myeloma can be cured one day

Dr. Kumar, Professor of Hematology, Mayo Clinic, Rochester, provides his thoughts on whether multiple myeloma can be cured one day

video

Shaji Kumar, MD, discusses sequencing agents in the treatment of multiple myeloma

Dr. Kumar, Professor of Hematology, Mayo Clinic, Rochester, shares his thoughts on what physicians should be aware of when ...

video

Shaji Kumar, MD, explains the impact personalized medicine will have on treatment of MM

Dr. Kumar, Professor of Hematology, Mayo Clinic, Rochester, shares his thoughts on personalized medicine and its impact on the treatment ...

video

Shaji Kumar, MD, explains how immunotherapies are being integrated into treatment algorithms for MM

Dr. Kumar, Professor of Hematology, Mayo Clinic, Rochester, explains how immunotherapies are being integrated into multiple myeloma treatment algorithms

video

Aref Al-Kali, MD, explains how the CPX 351 data may impact how AML patients are treated if approved

Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, explains how the CPX 351 data may impact the market and how ...

video

Matthew Davids, MD, relays the most exciting clinical advances in CLL at ASH 2016

Dr. Davids, Associate Director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, on ...

video

Eunice Wang, MD, on exciting news stemming from this year’s ASH meeting in the treatment for ALL

Dr. Wang, Professor of Oncology, Department of Medicine Chief, Leukemia Service, Roswell Park Cancer Center, gives her view on exciting ...

video

Nikhil C. Munshi, MD, discusses the goals for the multiple myeloma genome project

Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, relays the end goals for the multiple ...

video

Nikhil Munshi, MD, explains how the multiple myeloma genome project will personalize treatment of MM

Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, on how the multiple myeloma genome project ...

video

Alexander Perl, MD, discusses how molecular testing can facilitate decision making in AML patients

Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, on how molecular testing can be used to ...

video

Alexander Perl, MD, on how the BEAT AML master trial will change the way AML patients are treated

Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, talks about how the BEAT AML master trial ...

video

Swaminathan Iyer, MD, discusses how to incorporate ofatumumab into the treatment of CLL

Dr. Iyer, Co-Director Cockrell Center for Advanced Therapeutics, on how physicians should incorporate ofatumumab into the treatment of untreated CLL ...

video

Jeffrey Jones, MD relays the outcomes in his study for refractory, progressing CLL patients

Dr. Jones, Associate Professor of Medicine, The Ohio State University, The James Cancer Hospital, talks about the outcomes in his ...

video

Swaminathan Iyer, MD, on how romidepsin can be incorporated into the treatment of T cell lymphoma

Dr. Iyer, Co-Director Cockrell Center for Advanced Therapeutics, discusses how romidepsin should be incorporated into the treatment of patients with ...

video

C. Ola Landgren, MD, PhD, relays his thoughts on the most exciting news at ASH for MM patients

Dr. Landgren, Chief, Myeloma Service, Memorial Sloan Kettering, on what he found to be the most exciting news at ASH ...

video

C. Ola Landgren, MD, PhD, opines on how to base treatment decisions on MRD test results

Dr. Landgren, Chief, Myeloma Service, Memorial Sloan Kettering, on how physicians should base treatment decisions on MRD test results for ...

video

Jane Winter, MD, relays the most exciting news at ASH 2016 for NHL patients

Dr. Winter, MD, Northwestern Univ. Feinberg School of Medicine, Professor of Medicine, on her findings of the most exciting news ...

video

Jane Winter, MD, talks about how personalized medicine is being applied to NHL

Dr. Winter, Northwestern Univ. Feinberg School of Medicine, Professor of Medicine, weighs in on how personalized medicine is being applied ...

video

David Miklos, MD, discusses the outcomes in the phase 2 ibrutinib study for chronic GvHD

Dr. Miklos, Associate Professor of Medicine, Blood and Marrow Transplantation, Stanford University, explains the phase 2 ibrutinib study outcomes for ...

video

David Miklos, MD, on the impact stem cell and bone marrow transplant have on patients

Dr. Miklos, Associate Professor of Medicine, Blood and Marrow Transplantation, Stanford University, on how stem cell and bone marrow transplant ...

video

Jeffrey Jones, MD, talks about the unmet medical need based on significant advances for CLL patients

Dr. Jones, Associate Professor of Medicine, The Ohio State University, The James Cancer Hospital, speaks about the unmet medical need ...

video

Frederick L. Locke, MD, discusses the results of the ZUMA-1 pivotal phase 2 study with KTE-C19

Dr. Locke, Service Chief of the Immune and Cellular Therapy Program, Moffitt Cancer Center, discusses the results of the ZUMA-1 ...

video

Frederick L. Locke, MD, discusses what new targets could make CAR-T therapies more effective

Dr. Locke, Service Chief of the Immune and Cellular Therapy Program, Moffitt Cancer Center, discusses what new targets could make ...

video

Sattva Neelapu, MD, discusses the results of the ZUMA-1 pivotal phase 2 study with KTE-C19

Dr. Neelapu, Director of Laboratory and Translational Research, MD Anderson Cancer Center, discusses the results of the ZUMA-1 pivotal phase ...

video

Sattva Neelapu, MD, explains what the results of ZUMA-1 mean to DLBCL patients

Dr. Neelapu, Director of Laboratory and Translational Research, MD Anderson Cancer Center, explains what the results of ZUMA-1 mean to ...

video

Edward Copelan, MD, discusses the Levine Cancer Institute Program

Dr. Copelan, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, talks about his Levine Cancer Institute program

video

Andrzej Jakubowiak, MD, PhD, on the role of selinexor and the STORM trial and its future development

Dr. Jakubowiak, University of Chicago, Professor of Medicine; Director, Myeloma Program, talks about the role of selinexor and the STORM ...

video

Eunice Wang, MD, talks about the challenges in treating elderly patients with AML

Dr. Wang, Professor of Oncology, Department of Medicine Chief, Leukemia Service, Roswell Park Cancer Center, discusses challenges and strategies to ...

video

Matthew Davids, MD, talks about the advances in CLL and the unmet medical need for these patients

Dr. Davids, Associate Director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, talks about the advances in CLL and the ...

video

Susan O’Brien, MD, shares her thoughts on the advancements in the treatment of leukemia at ASH 2016

Dr. O’Brien, Professor of Medicine, University of California, Irvine, shares her thoughts on the advancements in the treatment of leukemia ...

video

Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL

Dr. Prince, Professor, The University of Melbourne and Monash University, talks about the outcomes of the ALCANZA study in CD30-expressing ...

video

Chadi Nabhan, MD, on incorporating clinical pathways into CLL and other hematologic malignancies

Dr. Nabhan, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, discusses how clinical pathways are being incorporated into ...

video

Chadi Nabhan, MD, weighs in on the treatment of elderly patients with hematological malignancies

Dr. Nabhan, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, provides insight on how elderly patients with hematological ...

video

Michael Kauffman, MD, on evidence that Selinexor is helping relapsed, refractory MM patients

Dr. Kauffman, CEO Karyopharm Therapeutics, explains the clinical evidence on Selinexor that is helping relapsed, refractory multiple myeloma patients

video

Michael Kauffman, MD, on how Selinexor works

Dr. Kauffman, CEO Karyopharm Therapeutics, on how Selinexor works

video

Aref Al-Kali, MD, discusses CPX 351 in older high-risk patients in AML

Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, discusses CPX 351 in older high-risk patients in AML

video

Aref Al-Kali, MD, talks about the importance of the AGIOS 221 data

Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, talks about the importance of the AGIOS 221 data

video

Lauren Pinter-Brown, MD, updates us on the important studies in cutaneous lymphomas presented at ASH

Dr. Pinter-Brown, Professor of Medicine and Dermatology, UC Irvine, updates us on the important studies in cutaneous lymphomas presented at ...

video

Lauren Pinter-Brown, MD, updates us on the important studies in T-cell lymphomas presented at ASH

Dr. Pinter-Brown, Professor of Medicine and Dermatology, UC Irvine, updates us on the important studies in T-cell lymphomas presented at ...

video

Edward Copelan, MD, on how he reduced the number of days for donors to provide cells for autologous BMT

Dr. Copelan, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, on how he reduced the number of ...

video

Andrzej Jakubowiak, MD, PhD, on the key takeaways from presentations at ASH 2016 on KRD

Dr. Jakubowiak, University of Chicago, Professor of Medicine; Director, Myeloma Program, talks bout the key takeaways from ASH 2016 presentation ...

video

Parameswaran Hari, MD, discusses the latest developments in stem cell transplantation at ASH 2016

Dr. Hari, Professor of Hematology, Medical College of Wisconsin, discusses the latest developments in stem cell transplantation here at ASH ...

video

Shaji Kumar, MD, discusses the most exciting treatment options for multiple myeloma today

Dr. Kumar, Professor of Medicine, Mayo Clinic, Rochester, shares his thoughts on the most exciting treatment options available in multiple ...

video

Parameswaran Hari, MD, explains the effectiveness of novel immunotherapies in the treatment of multiple myeloma

Dr. Hari, Professor of Hematology, Medical College of Wisconsin, explains the effectiveness of novel immunotherapies in the treatment of multiple ...

video

Susan O’Brien, MD, discusses CLL presentations at ASH 2016

Dr. O’Brien, Professor of Medicine, University of California, Irvine, discusses CLL presentations at ASH 2016

video

Shaji Kumar, MD, discusses selinexor and why it stands out as one of the most promising compounds being presented at ASH 2016 (part 2)

Dr. Kumar, Professor of Medicine, Mayo Clinic, Rochester, discusses selinexor (KPT-330) and why it stands out as one of the ...

video

Shaji Kumar, MD, discusses venetoclax and why it stands out as one of the most promising compounds being presented at ASH 2016

Dr. Kumar, Professor of Medicine, Mayo Clinic, Rochester, discusses venetoclax and why it stands out as one of the most ...

Related Videos

video-image

Sattva Neelapu, MD, on new targets being evaluated which could make CAR-T therapies more effective

video-image

Sattva Neelapu, MD, on the possibility to enhance T-cell proliferation for a higher response rate

video-image

Sattva Neelapu, MD, on when we may see widespread availability of CAR-T therapies

video-image

Matthew Davids, MD, MMSc, on the potential benefits of utilizing checkpoint blockade

video-image

Matthew Davids, MD, MMSc, talks about his ASH 2016 presentations

video-image

Eunice Wang, MD, on the importance of drug potency in the treatment of FLT3-ITD positive AML

video-image

Andrzej Jakubowiak, MD, PhD, discusses which new drugs are most compelling

video-image

Andrzej Jakubowiak, MD, PhD, relays big changes in the evolving role of immunomodulatory therapy

video-image

Michael Kauffman, MD, on Selinexor regulatory and commercialization plans

video-image

Jeffrey Jones, MD, on the exciting CLL clinical advances presented at ASH 2016

video-image

Edward Copelan, MD, on the most exciting presentations coming out of ASH 2016

video-image

David Miklos, MD, on developing an orphan drug for a small population of patients

video-image

Miles Prince, MD, on if any positive news for CTCL patients will be coming out of ASH 2016

video-image

Miles Prince, MD, on how CTCL patients will be impacted by treatment with brentuximab vedotin

video-image

Jane Winter, MD, on how immunotherapies are being incorporated into treatment for lymphoma patients

video-image

C. Ola Landgren, MD, PhD, on his optimism about the use of immunotherapies to treat MM patients

video-image

C. Ola Landgren, MD, PhD, provides insight into the treatment algorithm for smoldering MM patients

video-image

C. Ola Landgren, MD, PhD, on which multiple myeloma should be tested for MRD and why

video-image

C. Ola Landgren, MD, PhD, on how physicians should manage patients who test MRD negative

video-image

Swaminathan Iyer, MD, discusses exciting new CLL treatment options

video-image

Swaminathan Iyer, MD, relays the latest T cell lymphomas news coming out of ASH 2016

video-image

Swaminathan Iyer, MD, discusses intriguing data on CLL presented at ASH 2016

video-image

Alexander Perl, MD, on AML trial results presented at this year’s ASH meeting

video-image

Alexander Perl, MD, discusses treatment options for patients with FLT3-ITD positive AML

video-image

Alexander Perl, MD, on prognosis, diagnosis and treatment strategies for AML

video-image

Alexander Perl, MD, discusses treatment options for AML patients

video-image

Chadi Nabhan, MD, on attention grabbing presentation in CLL at ASH 2016

video-image

Chadi Nabhan, MD, on payers using clinical pathways in hematological malignancies vs solid tumors

video-image

Nikhil C. Munshi, MD, discusses his optimism about the use of immunotherapies to treat MM patients

video-image

Nikhil C. Munshi, MD, on whether we can start to associate the word “cure” with MM patients

video-image

Nikhil C. Munshi, MD, discusses the exciting news at ASH multiple myeloma patients

video-image

Nikhil C. Munshi, MD, on how physicians should sequence therapies in untreated MM patients

video-image

Lauren Pinter-Brown, MD, on improving quality of life for patients with T-cell lymphomas

video-image

Lauren Pinter-Brown, MD, explains refractory vs. relapsed peripheral T-cell lymphoma patients

video-image

Frederick Locke, MD, on the timing of when we could see widespread availability of CAR-T therapies

video-image

Frederick Locke, MD, on if CAR-T may replace transplantation when treating B-cell lymphomas

video-image

Frederick Locke, MD, explains the ZUMA-1 results and what it means to DLBCL patients

video-image

Parameswaran Hari, MD, talks about which stem cell transplantation studies are most exciting in MM

video-image

Parameswaran Hari, MD, on stem cell transplant and the treatment of high and low risk MM patients

video-image

Parameswaran Hari, MD, discusses stem cell transplantation and the treatment of myeloma

video-image

Aref Al-Kali, MD, explains sustained inhibition of FLT3 when treating AML patients

video-image

Aref Al-Kali, MD, reflects on the BEAT AML master trial and individualized therapy for AML patients

video-image

Aref Al-Kali, MD, explains how the CPX 351 data may impact how AML patients are treated if approved

video-image

Shaji Kumar, MD, shares his thoughts on whether multiple myeloma can be cured one day

video-image

Shaji Kumar, MD, discusses sequencing agents in the treatment of multiple myeloma

video-image

Shaji Kumar, MD, explains the impact personalized medicine will have on treatment of MM

video-image

Shaji Kumar, MD, explains how immunotherapies are being integrated into treatment algorithms for MM

video-image

Michael Kauffman, MD, on evidence that Selinexor is helping relapsed, refractory MM patients

video-image

Michael Kauffman, MD, on how Selinexor works

video-image

Chadi Nabhan, MD, on incorporating clinical pathways into CLL and other hematologic malignancies

video-image

Chadi Nabhan, MD, weighs in on the treatment of elderly patients with hematological malignancies

video-image

Eunice Wang, MD, on exciting news stemming from this year’s ASH meeting in the treatment for ALL

video-image

Matthew Davids, MD, relays the most exciting clinical advances in CLL at ASH 2016

video-image

Andrzej Jakubowiak, MD, PhD, on the key takeaways from presentations at ASH 2016 on KRD

video-image

Matthew Davids, MD, talks about the advances in CLL and the unmet medical need for these patients

video-image

Eunice Wang, MD, talks about the challenges in treating elderly patients with AML

video-image

Andrzej Jakubowiak, MD, PhD, on the role of selinexor and the STORM trial and its future development

video-image

Jeffrey Jones, MD relays the outcomes in his study for refractory, progressing CLL patients

video-image

Jeffrey Jones, MD, talks about the unmet medical need based on significant advances for CLL patients

video-image

Edward Copelan, MD, on how he reduced the number of days for donors to provide cells for autologous BMT

video-image

Edward Copelan, MD, discusses the Levine Cancer Institute Program

video-image

David Miklos, MD, on the impact stem cell and bone marrow transplant have on patients

video-image

David Miklos, MD, discusses the outcomes in the phase 2 ibrutinib study for chronic GvHD

video-image

Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL

video-image

Jane Winter, MD, talks about how personalized medicine is being applied to NHL

video-image

Jane Winter, MD, relays the most exciting news at ASH 2016 for NHL patients

video-image

C. Ola Landgren, MD, PhD, opines on how to base treatment decisions on MRD test results

video-image

C. Ola Landgren, MD, PhD, relays his thoughts on the most exciting news at ASH for MM patients

video-image

Swaminathan Iyer, MD, on how romidepsin can be incorporated into the treatment of T cell lymphoma

video-image

Swaminathan Iyer, MD, discusses how to incorporate ofatumumab into the treatment of CLL

video-image

Alexander Perl, MD, on how the BEAT AML master trial will change the way AML patients are treated

video-image

Alexander Perl, MD, discusses how molecular testing can facilitate decision making in AML patients

video-image

Nikhil Munshi, MD, explains how the multiple myeloma genome project will personalize treatment of MM

video-image

Nikhil C. Munshi, MD, discusses the goals for the multiple myeloma genome project

video-image

Sattva Neelapu, MD, explains what the results of ZUMA-1 mean to DLBCL patients

video-image

Sattva Neelapu, MD, discusses the results of the ZUMA-1 pivotal phase 2 study with KTE-C19

video-image

Lauren Pinter-Brown, MD, updates us on the important studies in T-cell lymphomas presented at ASH

video-image

Lauren Pinter-Brown, MD, updates us on the important studies in cutaneous lymphomas presented at ASH

video-image

Frederick L. Locke, MD, discusses what new targets could make CAR-T therapies more effective

video-image

Frederick L. Locke, MD, discusses the results of the ZUMA-1 pivotal phase 2 study with KTE-C19

video-image

Susan O’Brien, MD, shares her thoughts on the advancements in the treatment of leukemia at ASH 2016

video-image

Susan O’Brien, MD, discusses CLL presentations at ASH 2016

video-image

Parameswaran Hari, MD, explains the effectiveness of novel immunotherapies in the treatment of multiple myeloma

video-image

Parameswaran Hari, MD, discusses the latest developments in stem cell transplantation at ASH 2016

video-image

Aref Al-Kali, MD, talks about the importance of the AGIOS 221 data

video-image

Aref Al-Kali, MD, discusses CPX 351 in older high-risk patients in AML

video-image

Shaji Kumar, MD, discusses venetoclax and why it stands out as one of the most promising compounds being presented at ASH 2016

video-image

Shaji Kumar, MD, discusses selinexor and why it stands out as one of the most promising compounds being presented at ASH 2016 (part 2)

video-image

Shaji Kumar, MD, discusses the most exciting treatment options for multiple myeloma today